2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170488
    CM-728 2925046-28-0 98%
    CM-728 is a oxazepine-naphthoquinone that has cytotoxic and bactericidal effect. CM-728 is a human peroxiredoxin-1 inhibitor. CM-728 is an oxidative stressor that affects mitochondrial function.
    CM-728
  • HY-170489
    Antifungal agent 123 98%
    Antifungal agent 123 (Compound 4b) exhibits good affinity to the oxidoreductase of Staphylococcus aureus or the membrane protein of Candida albicans, exhibits antibacterial and antifungal activities. Antifungal agent 123 scavenges free radical, exhibits antioxidant efficacy. Antifungal agent 123 inhibits the TLR signaling pathway, and exhibits anti-inflammatory efficacy.
    Antifungal agent 123
  • HY-170518
    IKZF-IN-1 98%
    IKZF-IN-1 (Compound I) is the molecular glue, that degrades ikaros zinc finger family (IKZF) IKZF 1/2/3/4, and can be used as an immunomodulator in research of cancer and viral infections.
    IKZF-IN-1
  • HY-170523
    RU-0415529 1358734-35-6 98%
    RU-0415529 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC50 of 356 nM. RU-0415529 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and the viral replication. RU-0415529 exhibits anti-infectious activity in mouse models.
    RU-0415529
  • HY-170586
    JAK05 98%
    JAK05 exhibits inhibitory activity against Helicobacter pylori, inhibits strains J63, J196 and J107 with MIC of 3-5 µg/mL. JAK05 exhibits binding affinity to H+/K+-ATPase, COX-1/2, TNF-α and PGE2, reveals antioxidant and anti-inflammatory activities. JAK05 exhibits anti-ulcer activity in rat ethanol-induced gastric ulcer models.
    JAK05
  • HY-170598
    HP211206 3119106-17-8 98%
    HP211206 is a SARS-CoV-2 main protease (Mpro) PROTAC degrader. HP211206 effectively degrades SARS-CoV-2 Mpro and its drug-resistant mutants. HP211206 has an IC50 of 181.9 nM and a DC50 of 621 nM for Mpro. HP211206 has antiviral activity.
    HP211206
  • HY-170605
    BA-AZT1 98%
    BA-AZT1 is the inhibitor for HBV polymerase and sodium taurocholate cotransporting polypeptide (NTCP). BA-AZT1 inhibits the secretion of viral capsid protein HBsAg and HBeAg with IC50 of 0.65 µM and 13.42 µM, inhibits the HBV DNA replication with an IC50 of 0.70 µM.
    BA-AZT1
  • HY-170609
    Antimicrobial agent-36 98%
    Antimicrobial agent-36 (Compound 8b) is an antimicrobial agent that significantly inhibits the level of DNA gyrase, with an IC50 value of 4.56 µM. Antimicrobial agent-36 can also be used for the preparation of nanopharmaceutical formulations, for the research and development of novel antibiotics.
    Antimicrobial agent-36
  • HY-170663
    β-1,4-GALT1-IN-1 98%
    β-1,4-GALT1-IN-1 (Compound 6) is a β-1,4-GALT1 inhibitor, with an IC50 value of 6.2 μM. β-1,4-GALT1-IN-1 can be used in many pathology investigations such as cancer, autoimmune diseases and viral infections.
    β-1,4-GALT1-IN-1
  • HY-170723
    JAK-IN-39 2250013-34-2 98%
    JAK-IN-39 (compound 11) is a JAK inhibitor that suppresses JAK1, JAK2, JAK3 with IC50 values of 0.05, 1.18, and 0.03 nM, respectively. JAK-IN-39 can inhibit the viability of TF-1 cells and also suppress the production of lymphocyte TNFα and INFγ in vitro.
    JAK-IN-39
  • HY-170747
    9-tert-Butyldoxycycline 233585-94-9 98%
    9-tert-Butyldoxycycline exhibits immunomodulatory activity, alters the polarization states polymorphonuclear neutrophils, and ameliorates the inflammatory response in ischemia-reperfusion injury model. 9-tert-Butyldoxycycline is the ligand for ‘Tet-On’ switch system.
    9-tert-Butyldoxycycline
  • HY-170767
    SARS-CoV-2-IN-109 98%
    SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC50=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC50=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM.
    SARS-CoV-2-IN-109
  • HY-170773
    Mtb-IN-9 924871-27-2 98%
    Mtb-IN-9 (Compound M1) is a specific Mtb inhibitor that inhibits MtbFadD32 and MtbFadD28 activity. Mtb-IN-9 curtails the Mtb survival in infected macrophages and reduces Mtb burden and tubercular granulomas in a chronic infection model of BALB/c mice. Mtb-IN-9 is promising for research of tuberculosis.
    Mtb-IN-9
  • HY-170799
    HNC-1664 2127358-36-3 98%
    HNC-1664 is the orally active inhibitor for RNA-dependent RNA polymerase (RdRP). HNC-1664 exhibits broad-spectrum antiviral activity against coronavirus (SARS-CoV-2 wildtype and its mutants XBB.1.18, HK.3.1, BF.7.14, BA.1HCoV-229E, HCoV-OC43) and arenavirus. HNC-1664 exhibits anti-infectious activity in SARS-CoV-2 Delta infected mouse models.
    HNC-1664
  • HY-171112
    KSP-1007 2380240-20-8
    KSP-1007 is a bicyclic boronate-based broad-spectrum β-lactamase inhibitor. KSP-1007 can effectively inhibit class A, B, C and D β-lactamases, including serine-type, metallo-type (such as NDM, VIM, IMP) and Acinetobacter baumannii OXA-type enzymes. KSP-1007 can enhance the antibacterial activity of Meropenem (HY-13678), reduce its MIC value, and be effective against carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. KSP-1007 can be used for the research of bacterial infection.
    KSP-1007
  • HY-171151
    CPZEN-45 737759-36-3
    CPZEN-45 is a bacterial translocase I inhibitor with potent anti-tuberculosis activity. CPZEN-45 is promising for research of tuberculosis.
    CPZEN-45
  • HY-171215
    ML901 2226228-02-8 98%
    ML901 is an antimalarial agent with an IC50 value of 2 nM against the malaria parasite. ML901 specifically inhibits the tyrosine tRNA synthetase of the malaria parasite (PfYRS) through "receptor hijacking". ML901 exhibits full life-cycle killing activity in the malaria mouse model. ML901 can be used for studying malaria parasite infection.
    ML901
  • HY-171261
    CID15997213 900134-28-3
    CID15997213 is a blood-brain barrier penetrating antiviral agent. CID15997213 targets the amino-terminal domain of the VEEV nonstructural protein 2 (nsP2). CID15997213 shows alphavirus-specific antiviral effect, inhibiting VEEV and Western equine encephalitis virus.
    CID15997213
  • HY-171317
    SMARt751 1616370-52-5 99.99%
    SMARt751 targets the transcriptional regulatory factor VirS, inhibits its DNA binding ability, upregulates the mymA operon expression, thereby activating Ethionamide (HY-B0276), enhancing the antimicrobial activity of Ethionamide. SMARt751 enhances the antibacterial activity of Ethionamide against M. tuberculosis, reverses the Ethionamide resistance. SMARt751 improves the antibacterial effect of Ethionamide and reduces its effective dose in mouse models.
    SMARt751
  • HY-171540
    AnCDA-IN-1 1185081-36-0 98%
    AnCDA-IN-1 (Compound J075-4187) is an inhibitor of chitin deacetylase (CDA) with antifungal activity. It has an IC50 of 4.24 μM against AnCDA of A. nidulans, a minimum inhibitory concentration (MIC) of 260 μg/mL against food spoilage fungi and plant pathogenic fungi, and a minimum fungicidal concentration (MFC) of 520 μg/mL. AnCDA-IN-1 can be used in the research of the antifungal field .
    AnCDA-IN-1
Cat. No. Product Name / Synonyms Application Reactivity